Indore Online Journal

Glioblastoma Multiforme Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia

 Breaking News
  • No posts were found

Glioblastoma Multiforme Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia

April 16
12:35 2024
Glioblastoma Multiforme Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia
The Glioblastoma Multiforme Market Forecast report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the 7MM.

DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioblastoma Multiforme Market Forecast

 

Some of the key facts of the Glioblastoma Multiforme Market Report: 

  • The Glioblastoma Multiforme market size was valued approximately USD 800 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • During the study period from 2019 to 2032, the United States holds the largest market share for GBM, surpassing the combined market size of the EU4, the United Kingdom, and Japan, which was approximately USD 550 million in 2021.
  • In November 2023, The Global Coalition for Adaptive Research (GCAR) and the Cure Brain Cancer Foundation (CBCF) have partnered to introduce the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial in Australia. This patient-focused, adaptive platform trial aims to evaluate various therapies for individuals with newly diagnosed and recurrent glioblastoma (GBM), a highly aggressive form of brain cancer, with the goal of registration.
  • In June 2023, Chimeric Therapeutics initiated a Phase 1B clinical trial targeting patients experiencing recurring and/or advancing Glioblastoma Multiforme (GBM). This trial aims to evaluate the safety and effectiveness of CHM 1101, the company’s innovative CLTX CAR T cell therapy.
  • In June 2022, Novartis declared that the US FDA has provided accelerated approval for TAFINLAR (dabrafenib) + MEKINIST (trametinib) to treat advanced tumors carrying the “BRAF V600E” mutation. This approval encompasses both adult and pediatric (above 6 years old) patients with high- and low-grade gliomas having this mutation, and whose tumors have advanced after previous treatment.
  • The National Cancer Institute’s estimations from 2015 indicate that approximately 22,850 adults received diagnoses of brain and other nervous system cancers, comprising 12,630 men and 10,280 women. Among these cases, it is reported that 15,320 individuals faced fatalities due to these diagnoses.
  • In 2021, the collective number of new cases of Glioblastoma Multiforme (GBM) across the Seven Major Markets (7MM) amounted to approximately 32,550 individuals. Specifically within the United States, the reported incident cases of GBM patients reached around 13,250 during the same period.
  • In the United States, the highest count of Glioblastoma Multiforme (GBM) patients falls within the age bracket of 55–64, constituting around ~3,580 cases in 2021. Conversely, the smallest number of patients were reported in the age group below 18, which amounted to 150 cases in 2021.
  • Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix,Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology,Inovio Pharmaceuticals, Northwest Biotherapeutics and others
  • Key Glioblastoma Multiforme Therapies: Durvalumab, DNX-2401, ONC201, DCVax-L, Regorafenib, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
  • The Glioblastoma Multiforme epidemiology based on gender analyzed that Glioblastoma Multiforme is more prevalent among males than females
  • The Glioblastoma Multiforme market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics.

 

Glioblastoma Multiforme Overview

Glioblastoma multiforme (GBM) is a type of aggressive brain tumor that develops from glial cells, which are supportive cells in the brain. It is the most common and deadliest form of primary brain cancer in adults. GBM tumors are highly malignant and tend to grow rapidly, infiltrating nearby brain tissue.

 

Get a Free sample for the Glioblastoma Multiforme Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

 

Glioblastoma Multiforme Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Glioblastoma Multiforme Epidemiology Segmentation:

The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Glioblastoma Multiforme
  • Prevalent Cases of Glioblastoma Multiforme by severity
  • Gender-specific Prevalence of Glioblastoma Multiforme
  • Diagnosed Cases of Episodic and Chronic Glioblastoma Multiforme

 

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiology Forecast

 

Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Glioblastoma Multiforme Therapies and Key Companies

  • Durvalumab: AstraZeneca
  • DNX-2401: DNAtrix
  • ONC201: Chimerix
  • DCVax-L: Northwest Therapeutics
  • Regorafenib: Bayer
  • Paxalisib(GDC-0084): Kazia Therapeutics
  • AV-GBM-1: Aivita Biomedical
  • MDNA55: Medicenna Therapeutics
  • VAL-083: Kintara Therapeutics

 

Discover more about therapies set to grab major Glioblastoma Multiforme market share @ Glioblastoma Multiforme Treatment Landscape

 

Glioblastoma Multiforme Market Strengths

  • Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for GBM
  • Owing to the launch of bevacizumab biosimilars, a reduction in cost burden can be witnessed

 

Glioblastoma Multiforme Market Opportunities

  • Numerous failed clinical trials suggest combination therapies willikely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties
  • Better prognostic markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly preventing disease progression

 

Scope of the Glioblastoma Multiforme Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix,Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology,Inovio Pharmaceuticals, Northwest Biotherapeutics, and others
  • Key Glioblastoma Multiforme Therapies: Durvalumab, DNX-2401, ONC201, DCVax-L, Regorafenib, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others
  • Glioblastoma Multiforme Therapeutic Assessment: Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies
  • Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme market drivers and Glioblastoma Multiforme market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Glioblastoma Multiforme Unmet Needs, KOL’s views, Analyst’s views, Glioblastoma Multiforme Market Access and Reimbursement 

 

To know more about Glioblastoma Multiforme companies working in the treatment market, visit @ Glioblastoma Multiforme Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Glioblastoma Multiforme Market Report Introduction

2. Executive Summary for Glioblastoma Multiforme

3. SWOT analysis of Glioblastoma Multiforme

4. Glioblastoma Multiforme Patient Share (%) Overview at a Glance

5. Glioblastoma Multiforme Market Overview at a Glance

6. Glioblastoma Multiforme Disease Background and Overview

7. Glioblastoma Multiforme Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioblastoma Multiforme 

9. Glioblastoma Multiforme Current Treatment and Medical Practices

10. Glioblastoma Multiforme Unmet Needs

11. Glioblastoma Multiforme Emerging Therapies

12. Glioblastoma Multiforme Market Outlook

13. Country-Wise Glioblastoma Multiforme Market Analysis (2019–2032)

14. Glioblastoma Multiforme Market Access and Reimbursement of Therapies

15. Glioblastoma Multiforme Market Drivers

16. Glioblastoma Multiforme Market Barriers

17.  Glioblastoma Multiforme Appendix

18. Glioblastoma Multiforme Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories